iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Nifty Pharma stocks remain under pressure; Lupin, Dr Reddy's outperform while Cadila drags

18 Jan 2022 , 01:29 PM

Bear Market
Nifty Pharma stocks remained bearish on Tuesday amid volatile markets as the Index trimmed heavy early losses but remained in the red zone. Lupin led the gains while DR Reddy was also bullish. Cadila, Glenmark, Granules India, Alkem Lab, and Divis Lab dragged the sector.

The investors continue to watch evoloving situation due to Omicran variant of Covid-19 and corporate earnings. 

The benchmark indices opened higher on Tuesday but soon slipped into the red, however, Asian markets were broadly mixed. At around 1.10 pm, BSE Sensex was trading at 61,366.58 up 57.67 points or 0.09% and Nifty50 at 18,303.00 down 5.10 points or 0.03%.

Nifty Pharma was trading at 13,842.10 down 20.35 points or 0.15%, touching a high of 962.00 and low of 937.00 during intraday trade on Tuesday.


Lupin after remaining under pressure on Monday, amid news of recalling 50,832 bottles of Gatifloxacin Ophthalmic Solution, an antibiotic used to treat bacterial infections of the eyes, rallied on Tuesday. The stock was trading at Rs959.35 per piece, up nearly 1.8%.

Dr Reddy's rose 0.8% at Rs4,709.90 per piece to lift performance of the sector.

Cadila dragged 2.1% at Rs28.90 per piece to emerge the top laggard in the sector. Glenmark was 1.56% lower while Granules India whed 1.24%.  Alkem Lab also was 1.05% on the downside and Divis Lab and Abott India dragged 0.86% each. Pfizer and Cipla also were in the deep red. 

Related Tags

  • Aurobindo Pharma share price
  • Biocon share price
  • Cadila Healthcare share price
  • Cipla share price
  • Coronavirus vaccine
  • Covid-19 new cases
  • Covid-19 vaccine
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.